Olmesartan Medoxomil Versus Losartan in Patients With Hypertension
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- Registration Number
- NCT00857285
- Lead Sponsor
- Daiichi Sankyo
- Brief Summary
The purpose of this study is to determine the efficacy and safety of oral administration of olmesartan medoxomil compared to losartan in subjects with mild to moderate hypertension.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
- Diastolic BP 95 mm Hg - 114 mm Hg inclusive
- No participation in any clinical trial for the last 3 months
Exclusion Criteria
- Secondary hypertension
- Malignant hypertension
- Severe arterial hypertension
- Significant cardiovascular disease
- History or clinical evidence of cerebrovascular, gastrointestinal, hematological, hepatic disease, myocardial infarction, or severe liver disorder
- Clinical evidence of renal disease, poorly controlled diabetes, known malabsorption syndromes, psychiatric/emotional problems
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 olmesartan medoxomil olmesartan medoxomil 2 losartan potassium losartan potassium
- Primary Outcome Measures
Name Time Method Mean Change of Sitting dBP From Baseline to Week 12 Baseline to 12 weeks The difference in the sitting diastolic blood pressure (dBP) at trough, i.e. 24±2 hours after drug administration, from base line to Week 12.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of olmesartan medoxomil compared to losartan in angiotensin II receptor blockade for essential hypertension?
How does the efficacy of olmesartan medoxomil compare to losartan in mild to moderate essential hypertension patients according to phase 3 trials?
What biomarkers correlate with blood pressure response to olmesartan medoxomil versus losartan in essential hypertension treatment?
What adverse event profiles distinguish olmesartan medoxomil from losartan in phase 3 hypertension trials?
How do olmesartan medoxomil and losartan compare to other ARBs like valsartan in managing essential hypertension?
Trial Locations
- Locations (3)
Kaohsiung Medical University Hospital
🇨🇳Kaohsiung, Taiwan
Chung Shun Medical University Hospital
🇨🇳Taichung City, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Kaohsiung Medical University Hospital🇨🇳Kaohsiung, Taiwan